Background
Left ventricular assist devices (LVAD) are increasingly used in patients with advanced heart failure, many of whom have been or will be implanted with an implantable cardioverter defibrillator (ICD). Interaction between both devices is a matter of concern. Subcutaneous ICD (S-ICD) obtains its signals through subcutaneous vectors, which poses special challenges with regards to adequate performance following LVAD implantation. 
.. Discussion
We reviewed the reported cases in PubMed about the concomitant use of S-ICD and LVAD. Seven case reports about the performance of S-ICD in patients with an LVAD were identified, with discordant results. From these articles, we analyse the potential causes for these differing results. Pump location and operating rates in LVAD, as well as changes in the subcutaneous-electrocardiogram detected by the S-ICD after LVAD implantation are related to sensing disturbances when used in the same patient.
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Learning points
• Subcutaneous ICD (S-ICD) sensing may be compromised after left ventricular assist device (LVAD) implantation due to electromagnetic interference and changes in QRS voltage.
• Subcutaneous ICD implantation in LVAD potential candidates should be avoided until further data can prove its safety and efficacy.
• When an LVAD is implanted in an S-ICD recipient, the defibrillator should be deactivated until a new evaluation of sensing vectors demonstrates appropriate detection.
Introduction
Left ventricular assist devices (LVAD) are being increasingly used in patients with end-stage heart failure, both as bridge to transplantation and destination therapy. Many of these patients are or will be recipients of an implantable cardioverter defibrillator (ICD). The interaction between both cardiac electronic devices represents a new source of potential pitfalls in the management of this growing population. Recent reviews have addressed this issue, 1,2 but most available data relate to transvenous ICD. The entirely subcutaneous ICD (S-ICD) has emerged as an alternative to transvenous ICD aimed to avoid lead-related complications. 3, 4 As a consequence, recent Guidelines for Sudden Death Prevention 5 recommend the use of S-ICD in patients in whom pacing for bradycardia or ventricular tachycardia termination is neither needed nor anticipated especially in patients with a high risk of infection or unsuitable vascular access. However, no limitations regarding S-ICD indication in patients with an implanted LVAD or in candidates to receive these devices are mentioned.
We describe a case of S-ICD sensing dysfunction after the implantation of an LVAD. Moreover, we conducted a systematic search in PubMed and identified seven case reports dealing with S-ICD behaviour in patients with an LVAD.
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Timeline
Case presentation
A 20-year-old man was diagnosed with congestive heart failure due to idiopathic dilated cardiomyopathy in 2014. He remained stable under medical treatment with enalapril, bisoprolol, and eplerenone until January 2017, when he was admitted because of worsening of heart failure, severe biventricular dysfunction and self-limiting sustained ventricular tachycardias. He was referred in February 2017 for ICD implantation and included on the cardiac transplant waiting list due to advanced heart failure status, in spite of treatment with furosemide, sacubitril/valsartan, bisoprolol, eplerenone, and chlorthalidone.
An EMBLEM MRI S-ICD TM (Boston Scientific) was implanted due to the presence of a thrombus in the right ventricle, after successful surface electrocardiogram (ECG) screening. At implant, ventricular detection test showed appropriate sensing in primary and alternate vectors. Secondary vector showed P wave-instead of QRSdetection due to low QRS amplitude ( Figure 1 ). Post-operative course was uneventful, and the patient was discharged from the hospital the following day.
The patient was admitted to hospital again in January 2018 because of congestive heart failure exacerbation. Physical examination showed undetectable blood pressure, jugular venous pressure of 10 cm, painful hepatomegaly of 2 cm, and a light oedema in both ankles. The heart rate was 98 b.p.m. without murmurs or extra cardiac sounds. He was treated with dobutamine and then with a 24-h cycle of levosimendan, with a good response, and discharged after 7 days. He was then closely followed in the outpatient clinic but after several ambulatory intermittent levosimendan cycles, a new admission was needed 20 days later because of clinical and analytical worsening (weight gain, oedemas, hypotension, exertional epigastralgia, and serum creatinine 2.3 mg/dL). After a careful echocardiographic and haemodynamic evaluation under low dose of dobutamine due to inotropic dependence, a HeartMate 3 TM (Left Ventricular Assist System, Abbott) device was indicated as bridge to transplantation. The S-ICD was deactivated before surgery and checked postimplantation, showing failure to appropriately sense QRS signals in all three vectors (Figure 2 ). Primary and secondary vectors showed an artefact due to electromagnetic interference (EMI) from the LVAD. Furthermore, low-voltage QRS and, intermittently, P waves were classified as noise ('N'). The alternate vector did not show any apparent EMI, but the device classified P wave as sensed ventricular activity ('S') while QRS were undersensed ( Figure 2) . A MATLAB softwaregenerated Fast-Fourier Transform plot confirmed the detection of a peak of frequency around 90 Hz correlated to HeartMate 3 TM operational rate (5100 rpm) ( Figure 3) . Both, EMI detection and QRS signal attenuation overrided an appropriate cardiac rhythm sensing, rendering the S-ICD useless. As a good tolerance of ventricular arrhythmias has been reported in LVAD recipients, 13 the patient was discharged with the S-ICD deactivated after an exhaustive information. Three months later, the patient received a heart transplant with an uneventful post-operative course.
Discussion
Two cases of HeartWare V R (HVAD, HeartWare International) implantation 6, 11 have been reported in patients with previously implanted S-ICD. In both, EMI were visible in primary and secondary vectors and QRS was classified as noise, while the alternate vector did not display EMI, similarly to our case. (Figure 2 ). An automatic or manual setup selects the best sensing vector for detection, storing a reference subcutaneous-ECG (S-ECG) that will be used for the S-ICD system detection algorithm. 3 The device detects all signal events and makes dynamic adjustments in sensitivity in order to detect both, normal cardiac rhythm and ventricular fibrillation. A band-pass filter allows signals between 3 and 40 Hz to pass on for QRS detection, attenuating potential noncardiac signals. A digital notch filter at 50 or 60 Hz (depending on time zone selected) is also implemented, filtering out the typical frequency of the electrical current. Non-cardiac signals overimposed upon the S-ECG are labelled as noise (N). When a signal is classified as noise, it will not be taking into account in the detection process (Figure 2 ). The S-ICD band-pass and the notch filters attenuate non-cardiac signals, though they do not eliminate them completely, especially those having relatively high amplitude (Figure 3) . Therefore, the occurrence of EMI detection from the LVAD by an S-ICD depends on the frequency (Hz) and signal amplitude. HeartMate II TM and Jarvik
2000
V R work at high rates while HeartWare V R and HeartMate 3 TM operate at lower rates, generating a signal with a main frequency bordering band-pass filters ( Table 1) . The amplitude of the signal detected by S-ICD generated from the LVAD depends on the proximity of the source to the detection vectors. All cases with EMI detection occurred in the primary and secondary vectors, involving the S-ICD generator, but never in the alternate (Figure 2) .
All reported patients with EMI detection had thoracic LVAD pump location, 6, 9, 11, 12 while two out of three cases with a correct cardiac signal detection had a Heart Mate II TM , which pump is contained in a subdiaphragmatic pocket (Figure 4) . 7, 8 A patient with a Jarvik 2000 V R , 10 with the pump located in the thorax, did sense correctly. Noteworthy, this latter device runs at a very high rate, which makes sensing of EMI less likely. In the two published cases of inappropriate shocks due to EMI detection, 9, 12 it is remarkable that the QRS was totally missing 9 or very diminished 12 in the selected sensing vector. In the absence of a detectable cardiac signal, the S-ICD automatic gain control makes detection of EMI possible despite its very low voltage. Finally, a QRS signal attenuation in sensing vectors after LVAD implantation is a common finding. 6, 9, 11, 12 S-ICD implantation should be avoided in LVAD potential candidates until further data can prove its safety and efficacy. If an LVAD is indicated in a patient with an S-ICD already implanted, the defibrillator should be deactivated until a new evaluation of sensing vectors demonstrates appropriate detection in at least one vector in several postures.
Future changes in S-ICD detection algorithms and improvements in their programmability are desirable and could help to overcome current limitations.
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